RT Journal Article SR Electronic T1 Analytical and clinical validation of a targeted-enhanced whole genome sequencing-based comprehensive genomic profiling test JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.12.18.23300049 DO 10.1101/2023.12.18.23300049 A1 Ferguson, Stephanie A1 Sriram, Shruthi A1 Wallace, Jonathan Kyle A1 Lee, Jeonghoon A1 Kim, Jung-Ah A1 Lee, Yoonsuh A1 Oh, Brian Baek-Lok A1 Lee, Won Chul A1 Lee, Sangmoon A1 Connolly-Strong, Erin YR 2024 UL http://medrxiv.org/content/early/2024/03/03/2023.12.18.23300049.abstract AB Evaluation of the test performance of the targeted enhanced whole-genome sequencing (TE-WGS) assay for comprehensive oncology genomic profiling. The analytical validation of the assay included sensitivity and specificity for single nucleotide variants (SNVs), insertions/deletions (indels), and structural variants (SVs), revealing a revealed a sensitivity of 99.8% for SNVs and 99.2% for indels. The PPV was 99.3% for SNVs and 98.7% for indels. Clinical validation was benchmarked against established orthogonal methods and demonstrated high concordance with reference methods in variant characterization. The TE-WGS assay enhances personalized cancer treatment by offering detailed genomic insights and the adaptability to include emerging biomarkers.Competing Interest StatementThe authors of the publication are employees of Inocras Inc.Funding StatementThis research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2022M3A9G101451221) along with Genome Insight Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical validation of the TE-WGS assay was performed using a selected cohort of residual patient samples (N = 56) obtained from a prospective cohort registry study (Ajou University Medical Center), based on the availability of adequate residual formalin-fixed paraffin-embedded (FFPE) material, blood, and/or DNA for comprehensive analysis. The chosen samples met the following inclusion criteria: a confirmed prior cancer diagnosis and patient age of ≥18 years at the time of sample collection. The study protocol received approval from the Ajou University Medical Center Independent Review Board, with all participants providing written informed consent in line with ethical standards set forth in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors